The Global Erythromelalgia Treatment Market was valued at USD 82.26 million in 2024 and is projected to reach USD 179.31 million by 2035. The market is expected to expand at a CAGR of 7.48% during the forecast period from 2025 to 2035, driven by increasing awareness of rare diseases and growing advancements in treatment options.
Rising Patient Awareness and Education
The erythromelalgia treatment market is growing, and one of the main reasons for this is that more people are becoming aware of the condition. When patients and healthcare professionals know more about erythromelalgia, they can spot the symptoms earlier and get the right treatment. Educational initiatives and awareness campaigns are helping expand the diagnosed patient population, supporting steady market growth.
Segment Insights of the Global Erythromelalgia Treatment Market
By Type
• Primary Erythromelalgia – Genetic condition requiring long-term symptom management.
• Secondary Erythromelalgia – Linked to underlying diseases and conditions.
By Treatment
• Anticonvulsants (Gabapentin, Pregabalin, Others) – Used to reduce nerve pain symptoms.
• Antidepressants (Amitriptyline, Duloxetine, Venlafaxine) – Help manage neuropathic pain and discomfort.
• Topical Agents (Lidocaine, Capsaicin, Others) – Provide localized pain relief for patients.
• Calcium Channel Blockers – Improve blood flow and reduce flare-ups.
• Others – Include alternative and supportive treatment approaches.
By Route of Administration
• Oral – Most common method for systemic symptom control.
• Topical – Direct application for localized pain relief.
By Distribution Channel
• Hospital Pharmacies – Provide medications during specialized clinical treatments.
• Retail Pharmacies – Accessible source for routine prescription medications.
• Online Pharmacies – Convenient access to medications and home delivery.
In North America and Europe, the market for erythromelalgia treatment is strong because these regions have good healthcare systems, do a lot of research, and have policies in place to support people with rare diseases. On the other hand, Asia Pacific and South America are seeing growth because more people are getting access to healthcare, pharmaceutical companies are expanding their operations, and there's an increase in clinical research activities.
Strategic Expansion into Specialty and Rare Disease Therapies
Some companies, like Amneal Pharmaceuticals, are doing well in this market by using their advanced manufacturing capabilities and research skills to make complex generic drugs and biosimilars. This strategy is helping them break into markets for unique and specialty drugs, including treatments for rare diseases like erythromelalgia.
Growing Clinical Recognition and Patient Advocacy
Better diagnostic tools and earlier detection are also contributing to the growth of the treatment market. As the market continues to grow, it's likely that we'll see more companies developing new treatments for erythromelalgia. This could include new medications, therapies, or other interventions designed to help manage the condition. With more options available, patients may have a better chance of finding a treatment that works for them, which could improve their quality of life.
Key Report Attributes
• Market Size 2024: USD 82.26 Million
• Market Size 2035: USD 179.31 Million
• CAGR (2025-2035): 7.48%
• Base Year: 2024
• Market Forecast Period: 2025-2035
Industry Segmentation Growth
• By Type: Primary Erythromelalgia - 7.68%, Secondary Erythromelalgia - 6.89%.
• By Treatment: Anticonvulsants - 8.49%, Antidepressants - 6.76%.
• By Route of Administration: Oral - 7.32%, Tropical - 8.05%.
• By Distribution Channel: Hospital Pharmacies - 6.79%, Retail Pharmacies - 7.59%.
圖表清單 List of Tables & Figures
LIST OF TABLES
TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT 44
TABLE 2 KEY PREVALENCE AND INCIDENCE DATA SUMMARY 48
TABLE 3 GLOBAL ERYTHROMELALGIA TREATMENT MARKET, BY TYPE, 2019–2035 (USD MILLION) 61
TABLE 4 GLOBAL ERYTHROMELALGIA TREATMENT MARKET, FOR PRIMARY ERYTHROMELALGIA, BY REGION, 2019–2035 (USD MILLION)62
TABLE 5 GLOBAL ERYTHROMELALGIA TREATMENT MARKET, FOR SECONDARY ERYTHROMELALGIA, BY REGION, 2019–2035 (USD MILLION)
62
TABLE 6 GLOBAL ERYTHROMELALGIA TREATMENT MARKET, BY TREATMENT, 2019–2035 (USD MILLION) 64
TABLE 7 GLOBAL ERYTHROMELALGIA TREATMENT MARKET, FOR ANTICONVULSANTS, BY REGION, 2019–2035 (USD MILLION) 65
TABLE 8 GLOBAL ERYTHROMELALGIA TREATMENT MARKET, FOR ANTICONVULSANTS, BY TYPE, 2019–2035 (USD MILLION) 66
TABLE 9 GLOBAL ERYTHROMELALGIA TREATMENT MARKET, FOR ASPIRIN, BY REGION, 2019–2035 (USD MILLION) 66
TABLE 10 GLOBAL ERYTHROMELALGIA TREATMENT MARKET, FOR ANTIDEPRESSANTS, BY REGION, 2019–2035 (USD MILLION) 67
TABLE 11 GLOBAL ERYTHROMELALGIA TREATMENT MARKET, FOR ANTIDEPRESSANTS, BY TYPE, 2019–2035 (USD MILLION) 67
TABLE 12 GLOBAL ERYTHROMELALGIA TREATMENT MARKET, FOR TOPICAL AGENTS, BY REGION, 2019–2035 (USD MILLION) 68
TABLE 13 GLOBAL ERYTHROMELALGIA TREATMENT MARKET, FOR TOPICAL AGENTS, BY TYPE, 2019–2035 (USD MILLION) 68
TABLE 14 GLOBAL ERYTHROMELALGIA TREATMENT MARKET, FOR CALCIUM CHANNEL BLOCKERS, BY REGION, 2019–2035 (USD MILLION)
69
TABLE 15 GLOBAL ERYTHROMELALGIA TREATMENT MARKET, FOR OTHERS, BY REGION, 2019–2035 (USD MILLION) 69
TABLE 16 GLOBAL ERYTHROMELALGIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD MILLION) 71
TABLE 17 GLOBAL ERYTHROMELALGIA TREATMENT MARKET, FOR ORAL, BY REGION, 2019–2035 (USD MILLION) 72
TABLE 18 GLOBAL ERYTHROMELALGIA TREATMENT MARKET, FOR TOPICAL, BY REGION, 2019–2035 (USD MILLION) 72
TABLE 19 GLOBAL ERYTHROMELALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 74
TABLE 20 GLOBAL ERYTHROMELALGIA TREATMENT MARKET, FOR HOSPITAL PHARMACIES, BY REGION, 2019–2035 (USD MILLION) 75
TABLE 21 GLOBAL ERYTHROMELALGIA TREATMENT MARKET, FOR RETAIL PHARMACIES, BY REGION, 2019–2035 (USD MILLION) 76
TABLE 22 GLOBAL ERYTHROMELALGIA TREATMENT MARKET, FOR ONLINE PHARMACIES, BY REGION, 2019–2035 (USD MILLION) 76
TABLE 23 GLOBAL ERYTHROMELALGIA TREATMENT MARKET, BY REGION, 2019-2035 (USD MILLION) 77
TABLE 24 NORTH AMERICA ERYTHROMELALGIA TREATMENT MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 79
TABLE 25 NORTH AMERICA: ERYTHROMELALGIA TREATMENT MARKET, BY TYPE, 2019-2035 (USD MILLION) 80
TABLE 26 NORTH AMERICA: ERYTHROMELALGIA TREATMENT MARKET, BY TREATMENT, 2019-2035 (USD MILLION) 80
TABLE 27 NORTH AMERICA: ERYTHROMELALGIA TREATMENT MARKET, BY ANTICONVULSANTS, 2019-2035 (USD MILLION) 80
TABLE 28 NORTH AMERICA: ERYTHROMELALGIA TREATMENT MARKET, BY ANTIDEPRESSANTS, 2019-2035 (USD MILLION) 81
TABLE 29 NORTH AMERICA: ERYTHROMELALGIA TREATMENT MARKET, BY TROPICAL AGENTS, 2019-2035 (USD MILLION) 81
TABLE 30 NORTH AMERICA: ERYTHROMELALGIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 81
TABLE 31 NORTH AMERICA: ERYTHROMELALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 82
TABLE 32 US: ERYTHROMELALGIA TREATMENT MARKET, BY TYPE, 2019-2035 (USD MILLION) 82
TABLE 33 US: ERYTHROMELALGIA TREATMENT MARKET, BY TREATMENT, 2019-2035 (USD MILLION) 82
TABLE 34 US: ERYTHROMELALGIA TREATMENT MARKET, BY ANTICONVULSANTS, 2019-2035 (USD MILLION) 83
TABLE 35 US: ERYTHROMELALGIA TREATMENT MARKET, BY ANTIDEPRESSANTS, 2019-2035 (USD MILLION) 83
TABLE 36 US: ERYTHROMELALGIA TREATMENT MARKET, BY TROPICAL AGENTS, 2019-2035 (USD MILLION) 83
TABLE 37 US: ERYTHROMELALGIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 84
TABLE 38 US: ERYTHROMELALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 84
TABLE 39 CANADA: ERYTHROMELALGIA TREATMENT MARKET, BY TYPE, 2019-2035 (USD MILLION) 84
TABLE 40 CANADA: ERYTHROMELALGIA TREATMENT MARKET, BY TREATMENT, 2019-2035 (USD MILLION) 85
TABLE 41 CANADA: ERYTHROMELALGIA TREATMENT MARKET, BY ANTICONVULSANTS, 2019-2035 (USD MILLION) 85
TABLE 42 CANADA: ERYTHROMELALGIA TREATMENT MARKET, BY ANTIDEPRESSANTS, 2019-2035 (USD MILLION) 85
TABLE 43 CANADA: ERYTHROMELALGIA TREATMENT MARKET, BY TROPICAL AGENTS, 2019-2035 (USD MILLION) 86
TABLE 44 CANADA: ERYTHROMELALGIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 86
TABLE 45 CANADA: ERYTHROMELALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 86
TABLE 46 EUROPE ERYTHROMELALGIA TREATMENT MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 88
TABLE 47 EUROPE: ERYTHROMELALGIA TREATMENT MARKET, BY TYPE, 2019-2035 (USD MILLION) 88
TABLE 48 EUROPE: ERYTHROMELALGIA TREATMENT MARKET, BY TREATMENT, 2019-2035 (USD MILLION) 89
TABLE 49 EUROPE: ERYTHROMELALGIA TREATMENT MARKET, BY ANTICONVULSANTS, 2019-2035 (USD MILLION) 89
TABLE 50 EUROPE: ERYTHROMELALGIA TREATMENT MARKET, BY ANTIDEPRESSANTS, 2019-2035 (USD MILLION) 89
TABLE 51 EUROPE: ERYTHROMELALGIA TREATMENT MARKET, BY TROPICAL AGENTS, 2019-2035 (USD MILLION) 90
TABLE 52 EUROPE: ERYTHROMELALGIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 90
TABLE 53 EUROPE: ERYTHROMELALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 90
TABLE 54 GERMANY: ERYTHROMELALGIA TREATMENT MARKET, BY TYPE, 2019-2035 (USD MILLION) 91
TABLE 55 GERMANY: ERYTHROMELALGIA TREATMENT MARKET, BY TREATMENT, 2019-2035 (USD MILLION) 91
TABLE 56 GERMANY: ERYTHROMELALGIA TREATMENT MARKET, BY ANTICONVULSANTS, 2019-2035 (USD MILLION) 91
TABLE 57 GERMANY: ERYTHROMELALGIA TREATMENT MARKET, BY ANTIDEPRESSANTS, 2019-2035 (USD MILLION) 92
TABLE 58 GERMANY: ERYTHROMELALGIA TREATMENT MARKET, BY TROPICAL AGENTS, 2019-2035 (USD MILLION) 92
TABLE 59 GERMANY: ERYTHROMELALGIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 92
TABLE 60 GERMANY: ERYTHROMELALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 93
TABLE 61 UK: ERYTHROMELALGIA TREATMENT MARKET, BY TYPE, 2019-2035 (USD MILLION) 93
TABLE 62 UK: ERYTHROMELALGIA TREATMENT MARKET, BY TREATMENT, 2019-2035 (USD MILLION) 93
TABLE 63 UK: ERYTHROMELALGIA TREATMENT MARKET, BY ANTICONVULSANTS, 2019-2035 (USD MILLION) 94
TABLE 64 UK: ERYTHROMELALGIA TREATMENT MARKET, BY ANTIDEPRESSANTS, 2019-2035 (USD MILLION) 94
TABLE 65 UK: ERYTHROMELALGIA TREATMENT MARKET, BY TROPICAL AGENTS, 2019-2035 (USD MILLION) 94
TABLE 66 UK: ERYTHROMELALGIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 95
TABLE 67 UK: ERYTHROMELALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 95
TABLE 68 FRANCE ERYTHROMELALGIA TREATMENT MARKET, BY TYPE, 2019-2035 (USD MILLION) 95
TABLE 69 FRANCE ERYTHROMELALGIA TREATMENT MARKET, BY TREATMENT, 2019-2035 (USD MILLION) 96
TABLE 70 FRANCE ERYTHROMELALGIA TREATMENT MARKET, BY ANTICONVULSANTS, 2019-2035 (USD MILLION) 96
TABLE 71 FRANCE ERYTHROMELALGIA TREATMENT MARKET, BY ANTIDEPRESSANTS, 2019-2035 (USD MILLION) 96
TABLE 72 FRANCE ERYTHROMELALGIA TREATMENT MARKET, BY TROPICAL AGENTS, 2019-2035 (USD MILLION) 97
TABLE 73 FRANCE ERYTHROMELALGIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 97
TABLE 74 FRANCE ERYTHROMELALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 97
TABLE 75 RUSSIA ERYTHROMELALGIA TREATMENT MARKET, BY TYPE, 2019-2035 (USD MILLION) 98
TABLE 76 RUSSIA ERYTHROMELALGIA TREATMENT MARKET, BY TREATMENT, 2019-2035 (USD MILLION) 98
TABLE 77 RUSSIA ERYTHROMELALGIA TREATMENT MARKET, BY ANTICONVULSANTS, 2019-2035 (USD MILLION) 98
TABLE 78 RUSSIA ERYTHROMELALGIA TREATMENT MARKET, BY ANTIDEPRESSANTS, 2019-2035 (USD MILLION) 99
TABLE 79 RUSSIA ERYTHROMELALGIA TREATMENT MARKET, BY TROPICAL AGENTS, 2019-2035 (USD MILLION) 99
TABLE 80 RUSSIA ERYTHROMELALGIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 99
TABLE 81 RUSSIA ERYTHROMELALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 100
TABLE 82 ITALY: ERYTHROMELALGIA TREATMENT MARKET, BY TYPE, 2019-2035 (USD MILLION) 100
TABLE 83 ITALY: ERYTHROMELALGIA TREATMENT MARKET, BY TREATMENT, 2019-2035 (USD MILLION) 100
TABLE 84 ITALY: ERYTHROMELALGIA TREATMENT MARKET, BY ANTICONVULSANTS, 2019-2035 (USD MILLION) 101
TABLE 85 ITALY: ERYTHROMELALGIA TREATMENT MARKET, BY ANTIDEPRESSANTS, 2019-2035 (USD MILLION) 101
TABLE 86 ITALY: ERYTHROMELALGIA TREATMENT MARKET, BY TROPICAL AGENTS, 2019-2035 (USD MILLION) 101
TABLE 87 ITALY: ERYTHROMELALGIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 102
TABLE 88 ITALY: ERYTHROMELALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 102
TABLE 89 SPAIN: ERYTHROMELALGIA TREATMENT MARKET, BY TYPE, 2019-2035 (USD MILLION) 102
TABLE 90 SPAIN: ERYTHROMELALGIA TREATMENT MARKET, BY TREATMENT, 2019-2035 (USD MILLION) 103
TABLE 91 SPAIN: ERYTHROMELALGIA TREATMENT MARKET, BY ANTICONVULSANTS, 2019-2035 (USD MILLION) 103
TABLE 92 SPAIN: ERYTHROMELALGIA TREATMENT MARKET, BY ANTIDEPRESSANTS, 2019-2035 (USD MILLION) 103
TABLE 93 SPAIN: ERYTHROMELALGIA TREATMENT MARKET, BY TROPICAL AGENTS, 2019-2035 (USD MILLION) 104
TABLE 94 SPAIN: ERYTHROMELALGIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 104
TABLE 95 SPAIN: ERYTHROMELALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 104
TABLE 96 REST OF EUROPE: ERYTHROMELALGIA TREATMENT MARKET, BY TYPE, 2019-2035 (USD MILLION) 105
TABLE 97 REST OF EUROPE: ERYTHROMELALGIA TREATMENT MARKET, BY TREATMENT, 2019-2035 (USD MILLION) 105
TABLE 98 REST OF EUROPE: ERYTHROMELALGIA TREATMENT MARKET, BY ANTICONVULSANTS, 2019-2035 (USD MILLION) 105
TABLE 99 REST OF EUROPE: ERYTHROMELALGIA TREATMENT MARKET, BY ANTIDEPRESSANTS, 2019-2035 (USD MILLION) 106
TABLE 100 REST OF EUROPE: ERYTHROMELALGIA TREATMENT MARKET, BY TROPICAL AGENTS, 2019-2035 (USD MILLION) 106
TABLE 101 REST OF EUROPE: ERYTHROMELALGIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 106
TABLE 102 REST OF EUROPE: ERYTHROMELALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 107
TABLE 103 ASIA-PACIFIC: ERYTHROMELALGIA TREATMENT MARKET, BY COUNTRY, 2019–2035 (USD MILLION) 109
TABLE 104 ASIA-PACIFIC: ERYTHROMELALGIA TREATMENT MARKET, BY TYPE, 2019–2035 (USD MILLION) 110
TABLE 105 ASIA-PACIFIC: ERYTHROMELALGIA TREATMENT MARKET, BY TREATMENT, 2019–2035 (USD MILLION) 110
TABLE 106 ASIA-PACIFIC: ERYTHROMELALGIA TREATMENT MARKET, FOR ANTICONVULSANTS, BY TYPE, 2019–2035 (USD MILLION) 111
TABLE 107 ASIA-PACIFIC: ERYTHROMELALGIA TREATMENT MARKET, FOR ANTIDEPRESSANTS, BY TYPE, 2019–2035 (USD MILLION) 111
TABLE 108 ASIA-PACIFIC: ERYTHROMELALGIA TREATMENT MARKET, FOR TOPICAL AGENTS, BY TYPE, 2019–2035 (USD MILLION) 111
TABLE 109 ASIA-PACIFIC: ERYTHROMELALGIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD MILLION) 112
TABLE 110 ASIA-PACIFIC: ERYTHROMELALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 112
TABLE 111 CHINA: ERYTHROMELALGIA TREATMENT MARKET, BY TYPE, 2019–2035 (USD MILLION) 112
TABLE 112 CHINA: ERYTHROMELALGIA TREATMENT MARKET, BY TREATMENT, 2019–2035 (USD MILLION) 113
TABLE 113 CHINA: ERYTHROMELALGIA TREATMENT MARKET, FOR ANTICONVULSANTS, BY TYPE, 2019–2035 (USD MILLION) 113
TABLE 114 CHINA: ERYTHROMELALGIA TREATMENT MARKET, FOR ANTIDEPRESSANTS, BY TYPE, 2019–2035 (USD MILLION) 113
TABLE 115 CHINA: ERYTHROMELALGIA TREATMENT MARKET, FOR TOPICAL AGENTS, BY TYPE, 2019–2035 (USD MILLION) 114
TABLE 116 CHINA: ERYTHROMELALGIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD MILLION) 114
TABLE 117 CHINA: ERYTHROMELALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 114
TABLE 118 INDIA: ERYTHROMELALGIA TREATMENT MARKET, BY TYPE, 2019–2035 (USD MILLION) 115
TABLE 119 INDIA: ERYTHROMELALGIA TREATMENT MARKET, BY TREATMENT, 2019–2035 (USD MILLION) 115
TABLE 120 INDIA: ERYTHROMELALGIA TREATMENT MARKET, FOR ANTICONVULSANTS, BY TYPE, 2019–2035 (USD MILLION) 115
TABLE 121 INDIA: ERYTHROMELALGIA TREATMENT MARKET, FOR ANTIDEPRESSANTS, BY TYPE, 2019–2035 (USD MILLION) 116
TABLE 122 INDIA: ERYTHROMELALGIA TREATMENT MARKET, FOR TOPICAL AGENTS, BY TYPE, 2019–2035 (USD MILLION) 116
TABLE 123 INDIA: ERYTHROMELALGIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD MILLION) 116
TABLE 124 INDIA: ERYTHROMELALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 117
TABLE 125 JAPAN: ERYTHROMELALGIA TREATMENT MARKET, BY TYPE, 2019–2035 (USD MILLION) 117
TABLE 126 JAPAN: ERYTHROMELALGIA TREATMENT MARKET, BY TREATMENT, 2019–2035 (USD MILLION)
TABLE 127 JAPAN: ERYTHROMELALGIA TREATMENT MARKET, FOR ANTICONVULSANTS, BY TYPE, 2019–2035 (USD MILLION)
TABLE 128 JAPAN: ERYTHROMELALGIA TREATMENT MARKET, FOR ANTIDEPRESSANTS, BY TYPE, 2019–2035 (USD MILLION)
TABLE 129 JAPAN: ERYTHROMELALGIA TREATMENT MARKET, FOR TOPICAL AGENTS, BY TYPE, 2019–2035 (USD MILLION)
TABLE 130 JAPAN: ERYTHROMELALGIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD MILLION)
TABLE 131 JAPAN: ERYTHROMELALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION)
TABLE 132 SOUTH KOREA: ERYTHROMELALGIA TREATMENT MARKET, BY TYPE, 2019–2035 (USD MILLION)
TABLE 133 SOUTH KOREA: ERYTHROMELALGIA TREATMENT MARKET, BY TREATMENT, 2019–2035 (USD MILLION)
TABLE 134 SOUTH KOREA: ERYTHROMELALGIA TREATMENT MARKET, FOR ANTICONVULSANTS, BY TYPE, 2019–2035 (USD MILLION)
TABLE 135 SOUTH KOREA: ERYTHROMELALGIA TREATMENT MARKET, FOR ANTIDEPRESSANTS, BY TYPE, 2019–2035 (USD MILLION)
TABLE 136 SOUTH KOREA: ERYTHROMELALGIA TREATMENT MARKET, FOR TOPICAL AGENTS, BY TYPE, 2019–2035 (USD MILLION)
TABLE 137 SOUTH KOREA: ERYTHROMELALGIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD MILLION)
TABLE 138 SOUTH KOREA: ERYTHROMELALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION)
TABLE 139 MALAYSIA: ERYTHROMELALGIA TREATMENT MARKET, BY TYPE, 2019–2035 (USD MILLION)
TABLE 140 MALAYSIA: ERYTHROMELALGIA TREATMENT MARKET, BY TREATMENT, 2019–2035 (USD MILLION)
TABLE 141 MALAYSIA: ERYTHROMELALGIA TREATMENT MARKET, FOR ANTICONVULSANTS, BY TYPE, 2019–2035 (USD MILLION)
TABLE 142 MALAYSIA: ERYTHROMELALGIA TREATMENT MARKET, FOR ANTIDEPRESSANTS, BY TYPE, 2019–2035 (USD MILLION)
TABLE 143 MALAYSIA: ERYTHROMELALGIA TREATMENT MARKET, FOR TOPICAL AGENTS, BY TYPE, 2019–2035 (USD MILLION)
TABLE 144 MALAYSIA: ERYTHROMELALGIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD MILLION)
TABLE 145 MALAYSIA: ERYTHROMELALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION)
TABLE 146 THAILAND: ERYTHROMELALGIA TREATMENT MARKET, BY TYPE, 2019–2035 (USD MILLION)
TABLE 162 REST OF ASIA-PACIFIC: ERYTHROMELALGIA TREATMENT MARKET, FOR ANTICONVULSANTS, BY TYPE, 2019–2035 (USD MILLION)
129
TABLE 147 THAILAND: ERYTHROMELALGIA TREATMENT MARKET, BY TREATMENT, 2019–2035 (USD MILLION)
TABLE 148 THAILAND: ERYTHROMELALGIA TREATMENT MARKET, FOR ANTICONVULSANTS, BY TYPE, 2019–2035 (USD MILLION)
TABLE 149 THAILAND: ERYTHROMELALGIA TREATMENT MARKET, FOR ANTIDEPRESSANTS, BY TYPE, 2019–2035 (USD MILLION)
TABLE 150 THAILAND: ERYTHROMELALGIA TREATMENT MARKET, FOR TOPICAL AGENTS, BY TYPE, 2019–2035 (USD MILLION)
TABLE 151 THAILAND: ERYTHROMELALGIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD MILLION)
TABLE 152 THAILAND: ERYTHROMELALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION)
TABLE 153 INDONESIA: ERYTHROMELALGIA TREATMENT MARKET, BY TYPE, 2019–2035 (USD MILLION)
TABLE 154 INDONESIA: ERYTHROMELALGIA TREATMENT MARKET, BY TREATMENT, 2019–2035 (USD MILLION)
TABLE 155 INDONESIA: ERYTHROMELALGIA TREATMENT MARKET, FOR ANTICONVULSANTS, BY TYPE, 2019–2035 (USD MILLION)
TABLE 156 INDONESIA: ERYTHROMELALGIA TREATMENT MARKET, FOR ANTIDEPRESSANTS, BY TYPE, 2019–2035 (USD MILLION)
TABLE 157 INDONESIA: ERYTHROMELALGIA TREATMENT MARKET, FOR TOPICAL AGENTS, BY TYPE, 2019–2035 (USD MILLION)
TABLE 158 INDONESIA: ERYTHROMELALGIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD MILLION)
TABLE 159 INDONESIA: ERYTHROMELALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION)
TABLE 160 REST OF ASIA-PACIFIC: ERYTHROMELALGIA TREATMENT MARKET, BY TYPE, 2019–2035 (USD MILLION)
TABLE 161 REST OF ASIA-PACIFIC: ERYTHROMELALGIA TREATMENT MARKET, BY TREATMENT, 2019–2035 (USD MILLION)
TABLE 163 REST OF ASIA-PACIFIC: ERYTHROMELALGIA TREATMENT MARKET, FOR ANTIDEPRESSANTS, BY TYPE, 2019–2035 (USD MILLION)
130
TABLE 164 REST OF ASIA-PACIFIC: ERYTHROMELALGIA TREATMENT MARKET, FOR TOPICAL AGENTS, BY TYPE, 2019–2035 (USD MILLION)
130
TABLE 165 REST OF ASIA-PACIFIC: ERYTHROMELALGIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD MILLION)
130
TABLE 166 REST OF ASIA-PACIFIC: ERYTHROMELALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 131
TABLE 167 SOUTH AMERICA: ERYTHROMELALGIA TREATMENT MARKET, BY COUNTRY, 2019–2035 (USD MILLION)
132
TABLE 168 SOUTH AMERICA: ERYTHROMELALGIA TREATMENT MARKET, BY TYPE, 2019–2035 (USD MILLION)
TABLE 169 SOUTH AMERICA: ERYTHROMELALGIA TREATMENT MARKET, BY TREATMENT, 2019–2035 (USD MILLION)
TABLE 170 SOUTH AMERICA: ERYTHROMELALGIA TREATMENT MARKET, BY ANTICONVULSANTS, 2019–2035 (USD MILLION)
TABLE 171 SOUTH AMERICA: ERYTHROMELALGIA TREATMENT MARKET, BY ANTIDEPRESSANTS, BY TYPE, 2019–2035 (USD MILLION)
TABLE 172 SOUTH AMERICA: ERYTHROMELALGIA TREATMENT MARKET, BY TOPICAL AGENTS, 2019–2035 (USD MILLION)
TABLE 173 SOUTH AMERICA: ERYTHROMELALGIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD MILLION)
TABLE 174 SOUTH AMERICA: ERYTHROMELALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION)
TABLE 175 BRAZIL: ERYTHROMELALGIA TREATMENT MARKET, BY TYPE, 2019–2035 (USD MILLION)
TABLE 176 BRAZIL: ERYTHROMELALGIA TREATMENT MARKET, BY TREATMENT, 2019–2035 (USD MILLION)
TABLE 177 BRAZIL: ERYTHROMELALGIA TREATMENT MARKET, BY ANTICONVULSANTS, 2019–2035 (USD MILLION)
TABLE 178 BRAZIL: ERYTHROMELALGIA TREATMENT MARKET, BY ANTIDEPRESSANTS, BY TYPE, 2019–2035 (USD MILLION)
TABLE 179 BRAZIL: ERYTHROMELALGIA TREATMENT MARKET, BY TOPICAL AGENTS, 2019–2035 (USD MILLION)
TABLE 180 BRAZIL: ERYTHROMELALGIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD MILLION)
TABLE 181 BRAZIL: ERYTHROMELALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION)
TABLE 182 MEXICO: ERYTHROMELALGIA TREATMENT MARKET, BY TYPE, 2019–2035 (USD MILLION)
TABLE 183 MEXICO: ERYTHROMELALGIA TREATMENT MARKET, BY TREATMENT, 2019–2035 (USD MILLION)
TABLE 184 MEXICO: ERYTHROMELALGIA TREATMENT MARKET, BY ANTICONVULSANTS, 2019–2035 (USD MILLION)
TABLE 185 MEXICO: ERYTHROMELALGIA TREATMENT MARKET, BY ANTIDEPRESSANTS, BY TYPE, 2019–2035 (USD MILLION)
TABLE 186 MEXICO: ERYTHROMELALGIA TREATMENT MARKET, BY TOPICAL AGENTS, 2019–2035 (USD MILLION)
TABLE 187 MEXICO: ERYTHROMELALGIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD MILLION)
TABLE 188 MEXICO: ERYTHROMELALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION)
TABLE 189 ARGENTINA: ERYTHROMELALGIA TREATMENT MARKET, BY TYPE, 2019–2035 (USD MILLION)
TABLE 190 ARGENTINA: ERYTHROMELALGIA TREATMENT MARKET, BY TREATMENT, 2019–2035 (USD MILLION)
TABLE 191 ARGENTINA: ERYTHROMELALGIA TREATMENT MARKET, BY ANTICONVULSANTS, 2019–2035 (USD MILLION)
TABLE 192 ARGENTINA: ERYTHROMELALGIA TREATMENT MARKET, BY ANTIDEPRESSANTS, BY TYPE, 2019–2035 (USD MILLION)
TABLE 193 ARGENTINA: ERYTHROMELALGIA TREATMENT MARKET, BY TOPICAL AGENTS, 2019–2035 (USD MILLION)
TABLE 194 ARGENTINA: ERYTHROMELALGIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD MILLION)
TABLE 195 ARGENTINA: ERYTHROMELALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION)
TABLE 196 REST OF SOUTH AMERICA: ERYTHROMELALGIA TREATMENT MARKET, BY TYPE, 2019–2035 (USD MILLION)
TABLE 197 REST OF SOUTH AMERICA: ERYTHROMELALGIA TREATMENT MARKET, BY TREATMENT, 2019–2035 (USD MILLION)
TABLE 198 REST OF SOUTH AMERICA: ERYTHROMELALGIA TREATMENT MARKET, BY ANTICONVULSANTS, 2019–2035 (USD MILLION)
TABLE 199 REST OF SOUTH AMERICA: ERYTHROMELALGIA TREATMENT MARKET, BY ANTIDEPRESSANTS, BY TYPE, 2019–2035 (USD MILLION)
143
TABLE 200 REST OF SOUTH AMERICA: ERYTHROMELALGIA TREATMENT MARKET, BY TOPICAL AGENTS, 2019–2035 (USD MILLION)
144
TABLE 201 REST OF SOUTH AMERICA: ERYTHROMELALGIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD MILLION)
144
TABLE 202 REST OF SOUTH AMERICA: ERYTHROMELALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 144
TABLE 203 MIDDLE EAST AND AFRICA: ERYTHROMELALGIA TREATMENT MARKET, BY COUNTRY, 2019–2035 (USD MILLION)
146
TABLE 204 MIDDLE EAST & AFRICA: ERYTHROMELALGIA TREATMENT MARKET, BY TYPE, 2019–2035 (USD MILLION)
TABLE 205 MIDDLE EAST & AFRICA: ERYTHROMELALGIA TREATMENT MARKET, BY TREATMENT, 2019–2035 (USD MILLION)
TABLE 206 MIDDLE EAST & AFRICA: ERYTHROMELALGIA TREATMENT MARKET, BY ANTICONVULSANTS, 2019–2035 (USD MILLION)
TABLE 207 MIDDLE EAST & AFRICA: ERYTHROMELALGIA TREATMENT MARKET, BY ANTIDEPRESSANTS, BY TYPE, 2019–2035 (USD MILLION)
148
TABLE 208 MIDDLE EAST & AFRICA: ERYTHROMELALGIA TREATMENT MARKET, BY TOPICAL AGENTS, 2019–2035 (USD MILLION)
148
TABLE 209 MIDDLE EAST & AFRICA: ERYTHROMELALGIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD MILLION)
149
TABLE 210 MIDDLE EAST & AFRICA: ERYTHROMELALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 149
TABLE 211 GCC COUNTRIES: ERYTHROMELALGIA TREATMENT MARKET, BY TYPE, 2019–2035 (USD MILLION)
149
TABLE 212 GCC COUNTRIES: ERYTHROMELALGIA TREATMENT MARKET, BY TREATMENT, 2019–2035 (USD MILLION)
TABLE 213 GCC COUNTRIES: ERYTHROMELALGIA TREATMENT MARKET, BY ANTICONVULSANTS, 2019–2035 (USD MILLION)
TABLE 214 GCC COUNTRIES: ERYTHROMELALGIA TREATMENT MARKET, BY ANTIDEPRESSANTS, BY TYPE, 2019–2035 (USD MILLION)
TABLE 215 GCC COUNTRIES: ERYTHROMELALGIA TREATMENT MARKET, BY TOPICAL AGENTS, 2019–2035 (USD MILLION)
TABLE 216 GCC COUNTRIES: ERYTHROMELALGIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD MILLION)
TABLE 217 GCC COUNTRIES: ERYTHROMELALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION)
TABLE 218 SOUTH AFRICA: ERYTHROMELALGIA TREATMENT MARKET, BY TYPE, 2019–2035 (USD MILLION)
TABLE 219 SOUTH AFRICA: ERYTHROMELALGIA TREATMENT MARKET, BY TREATMENT, 2019–2035 (USD MILLION)
TABLE 220 SOUTH AFRICA: ERYTHROMELALGIA TREATMENT MARKET, BY ANTICONVULSANTS, 2019–2035 (USD MILLION)
TABLE 221 SOUTH AFRICA: ERYTHROMELALGIA TREATMENT MARKET, BY ANTIDEPRESSANTS, BY TYPE, 2019–2035 (USD MILLION)
TABLE 222 SOUTH AFRICA: ERYTHROMELALGIA TREATMENT MARKET, BY TOPICAL AGENTS, 2019–2035 (USD MILLION)
TABLE 223 SOUTH AFRICA: ERYTHROMELALGIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD MILLION)
TABLE 224 SOUTH AFRICA: ERYTHROMELALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION)
TABLE 225 REST OF MIDDLE EAST & AFRICA: ERYTHROMELALGIA TREATMENT MARKET, BY TYPE, 2019–2035 (USD MILLION)
TABLE 226 REST OF MIDDLE EAST & AFRICA: ERYTHROMELALGIA TREATMENT MARKET, BY TREATMENT, 2019–2035 (USD MILLION)
TABLE 227 REST OF MIDDLE EAST & AFRICA: ERYTHROMELALGIA TREATMENT MARKET, BY ANTICONVULSANTS, 2019–2035 (USD MILLION)
155
TABLE 228 REST OF MIDDLE EAST & AFRICA: ERYTHROMELALGIA TREATMENT MARKET, BY ANTIDEPRESSANTS, BY TYPE, 2019–2035 (USD
MILLION)
155
TABLE 229 REST OF MIDDLE EAST & AFRICA: ERYTHROMELALGIA TREATMENT MARKET, BY TOPICAL AGENTS, 2019–2035 (USD MILLION) 156
TABLE 230 REST OF MIDDLE EAST & AFRICA: ERYTHROMELALGIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD
MILLION)
156
TABLE 231 REST OF MIDDLE EAST & AFRICA: ERYTHROMELALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD
MILLION)
TABLE 232 BAYER AG: PRODUCTS OFFERED
TABLE 233 PFIZER INC.: PRODUCTS OFFERED
TABLE 234 TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCTS OFFERED
TABLE 235 TEVA PHARMACEUTICAL INDUSTRIES LTD: KEY DEVELOPMENTS
TABLE 236 ELI LILLY AND COMPANY: PRODUCTS OFFERED
TABLE 237 CIPLA CORPORATION: PRODUCTS OFFERED
TABLE 238 GLENMARK PHARMACEUTICALS LIMITED: PRODUCTS OFFERED
TABLE 239 SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT OFFERED
TABLE 240 VIATRIS INC.: PRODUCT OFFERED
TABLE 241 DR. REDDY'S LABORATORIES LTD.: PRODUCT OFFERED
TABLE 242 AMNEAL PHARMACEUTICALS LLC: PRODUCTS OFFERED
LIST OF FIGURES
FIGURE 1 MARKET ATTRACTIVENESS ANALYSIS: GLOBAL ERYTHROMELALGIA TREATMENT MARKET, 2024 22
FIGURE 2 GLOBAL ERYTHROMELALGIA TREATMENT MARKET ANALYSIS, BY TYPE, 2024 23
FIGURE 3 GLOBAL ERYTHROMELALGIA TREATMENT MARKET ANALYSIS, BY TREATMENT, 2024 24
FIGURE 4 GLOBAL ERYTHROMELALGIA TREATMENT MARKET ANALYSIS, BY ROUTE OF ADMINISTRATION, 2024 25
FIGURE 5 GLOBAL ERYTHROMELALGIA TREATMENT MARKET ANALYSIS, BY DISTRIBUTION CHANNEL, 2024 26
FIGURE 6 GLOBAL ERYTHROMELALGIA TREATMENT MARKET ANALYSIS, BY REGION, 2024 27
FIGURE 1 GLOBAL ERYTHROMELALGIA TREATMENT MARKET: STRUCTURE 30
FIGURE 2 GLOBAL ERYTHROMELALGIA TREATMENT MARKET: MARKET GROWTH FACTOR ANALYSIS (2019-2035) 47
FIGURE 3 DRIVER IMPACT ANALYSIS (2024-2035) 49
FIGURE 4 RESTRAINT IMPACT ANALYSIS (2024-2035) 50
FIGURE 5 PORTER'S FIVE FORCES ANALYSIS: GLOBAL ERYTHROMELALGIA TREATMENT MARKET 52
FIGURE 6 GLOBAL ERYTHROMELALGIA TREATMENT MARKET, BY TYPE SEGMENT ATTRACTIVENESS, 2024 & 2035 (USD MILLION) 60
FIGURE 7 GLOBAL ERYTHROMELALGIA TREATMENT MARKET, BY TYPE, 2024 & 2035 (USD MILLION) 60
FIGURE 8 GLOBAL ERYTHROMELALGIA TREATMENT MARKET SHARE (%), BY TYPE, 2024 61
FIGURE 9 GLOBAL ERYTHROMELALGIA TREATMENT MARKET, BY TREATMENT SEGMENT ATTRACTIVENESS, 2024 & 2035 (USD MILLION) 63
FIGURE 10 GLOBAL ERYTHROMELALGIA TREATMENT MARKET, BY TREATMENT, 2024 & 2035 (USD MILLION) 64
FIGURE 11 GLOBAL ERYTHROMELALGIA TREATMENT MARKET SHARE (%), BY TREATMENT, 2024 65
FIGURE 12 GLOBAL ERYTHROMELALGIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION SEGMENT ATTRACTIVENESS, 2024 & 2035 (USD
MILLION) 70
FIGURE 13 GLOBAL ERYTHROMELALGIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2024 & 2035 (USD MILLION) 70
FIGURE 14 GLOBAL ERYTHROMELALGIA TREATMENT MARKET SHARE (%), BY ROUTE OF ADMINISTRATION, 2024 71
FIGURE 15 GLOBAL ERYTHROMELALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL SEGMENT ATTRACTIVENESS, 2024 & 2035 (USD
MILLION) 73
FIGURE 16 GLOBAL ERYTHROMELALGIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2024 & 2035 (USD MILLION) 74
FIGURE 17 GLOBAL ERYTHROMELALGIA TREATMENT MARKET SHARE (%), BY DISTRIBUTION CHANNEL, 2024 75
FIGURE 18 GLOBAL ERYTHROMELALGIA TREATMENT MARKET, BY REGION, 2024 & 2035 (USD MILLION) 77
FIGURE 19 GLOBAL ERYTHROMELALGIA TREATMENT MARKET SHARE (%), BY REGION, 2024 78
FIGURE 20 NORTH AMERICA MARKET ANALYSIS: ERYTHROMELALGIA TREATMENT MARKET, 2019-2035 (USD MILLION) 78
FIGURE 21 NORTH AMERICA ERYTHROMELALGIA TREATMENT MARKET, BY COUNTRY, 2024 & 2035 (USD MILLION) 79
FIGURE 22 NORTH AMERICA ERYTHROMELALGIA TREATMENT MARKET SHARE (%), BY COUNTRY, 2024 79
FIGURE 23 EUROPE MARKET ANALYSIS: ERYTHROMELALGIA TREATMENT MARKET, 2019-2035 (USD MILLION) 87
FIGURE 24 EUROPE ERYTHROMELALGIA TREATMENT MARKET, BY REGION, 2024 & 2035 (USD MILLION) 87
FIGURE 25 EUROPE ERYTHROMELALGIA TREATMENT MARKET SHARE (%), BY COUNTRY, 2024 88
FIGURE 26 ASIA-PACIFIC MARKET ANALYSIS: ERYTHROMELALGIA TREATMENT MARKET, 2019-2035 (USD MILLION) 108
FIGURE 27 ASIA-PACIFIC: ERYTHROMELALGIA TREATMENT MARKET SHARE, BY COUNTRY, 2024 & 2035 (USD MILLION) 109
FIGURE 28 ASIA-PACIFIC: ERYTHROMELALGIA TREATMENT MARKET SHARE, BY COUNTRY, 2024 (%) 110
FIGURE 29 SOUTH AMERICA ERYTHROMELALGIA TREATMENT MARKET ANALYSIS: ERYTHROMELALGIA TREATMENT MARKET, 2019-2035 (USD
MILLION) 131
FIGURE 30 SOUTH AMERICA: ERYTHROMELALGIA TREATMENT MARKET SHARE, BY COUNTRY, 2024 & 2035 (USD MILLION) 132
FIGURE 31 SOUTH AMERICA: ERYTHROMELALGIA TREATMENT MARKET SHARE, BY COUNTRY, 2024 (%) 133
FIGURE 32 MIDDLE EAST & AFRICA MARKET ANALYSIS: ERYTHROMELALGIA TREATMENT MARKET, 2019-2035 (USD MILLION) 145
FIGURE 33 MIDDLE EAST AND AFRICA: ERYTHROMELALGIA TREATMENT MARKET SHARE, BY COUNTRY, 2024 & 2035 (USD MILLION) 146
FIGURE 34 MIDDLE EAST AND AFRICA: ERYTHROMELALGIA TREATMENT MARKET SHARE, BY COUNTRY, 2024 (%) 147
FIGURE 35 GLOBAL ERYTHROMELALGIA TREATMENT MARKET PLAYERS: COMPETITIVE ANALYSIS, 2024 158
FIGURE 36 COMPETITOR DASHBOARD: GLOBAL ERYTHROMELALGIA TREATMENT MARKET 159
FIGURE 37 BAYER AG: FINANCIAL OVERVIEW SNAPSHOT 163
FIGURE 38 PFIZER INC.: FINANCIAL OVERVIEW SNAPSHOT 167
FIGURE 39 PFIZER INC.: SWOT ANALYSIS 168
FIGURE 40 TEVA PHARMACEUTICAL INDUSTRIES LTD: FINANCIAL OVERVIEW SNAPSHOT 170
FIGURE 41 TEVA PHARMACEUTICAL INDUSTRIES LTD: SWOT ANALYSIS 171
FIGURE 42 ELI LILLY AND COMPANY: FINANCIAL OVERVIEW SNAPSHOT 174
FIGURE 43 CIPLA: FINANCIAL OVERVIEW SNAPSHOT 177
FIGURE 44 CIPLA: SWOT ANALYSIS 178
FIGURE 45 GLENMARK PHARMACEUTICALS LIMITED: FINANCIAL OVERVIEW SNAPSHOT 181
FIGURE 46 GLENMARK PHARMACEUTICALS LIMITED: SWOT ANALYSIS 182
FIGURE 47 SUN PHARMACEUTICAL INDUSTRIES LTD.: FINANCIAL OVERVIEW SNAPSHOT 185
FIGURE 48 SUN PHARMACEUTICAL INDUSTRIES LTD.: SWOT ANALYSIS 186
FIGURE 49 VIATRIS INC.: FINANCIAL OVERVIEW SNAPSHOT 189
FIGURE 50 DR. REDDY'S LABORATORIES LTD.: FINANCIAL OVERVIEW SNAPSHOT 192
FIGURE 51 AMNEAL PHARMACEUTICALS LLC.: FINANCIAL OVERVIEW SNAPSHOT 195
量子訊息有限公司為 Market Research Future 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們